Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from HER2+ breast cancer cell lines.

ABSTRACT: Expression data from HER2+ breast cancer cell lines.

PROVIDER: PRJNA812395 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from HER2+ breast cancer cell lines.

Project description:miRNA expression is often disregulated in cancer pathways, such as progression of resistance. We used microarrays in order to determine the differences in miRNA expression between breast cancer cell lines and their resistant pairs.

2022-03-06 | GSE197822 | GEO

HER2 Overexpression Modifies the Cellular Response to Hypoxia in MCF7 Breast Cancer Cell Lines

Project description:Tumour hypoxia is a recognised driver of breast cancer pathology. The main cellular response to hypoxia is mediated by the hypoxia-inducible factors HIF1 and HIF2, and is controlled through the regulation of oxygen-labile HIFα subunits. HIF1α has a well-established role in breast cancer where it has also been shown to be regulated by growth factor signalling. However, the role of HIF2α has been less thoroughly researched. Here, the role of HIF2α was investigated in breast cancer cell lines and publicly available gene expression datasets to determine its relationship with HER2 receptor expression in breast cancer. Using an isogenic cell line model for HER2 overexpression, we establish a direct role for HER2 in driving HIF2α expression in breast cancer. The effect of HER2-mediated HIF2α expression on the cellular response to acute and chronic hypoxia was investigated in 2D and 3D cell line models, and through protein and gene expression analysis, HER2 was shown to drive an exacerbated hypoxic response in these cells. In growth assays, HER2-overexpressing cell lines were shown to be highly sensitive to HIF2-specific inhibition through HIF2α-targeted siRNA and treatment with the HIF2α-specific translation inhibitor C76. Additionally, survival analysis in a large, publicly available dataset demonstrated a relationship between HIF2α and poor disease-specific survival in HER2-overexpressing tumours. We demonstrate a novel role for HIF2α in driving an increased hypoxic response in breast cancer cells and suggest HIF2 signalling may be an important, targetable pathway in HER2-positive breast cancers.

2018-03-01 | GSE111246 | GEO

Gene expression analysis of HER2+ breast leptomeningeal carcinomatosis

Project description:Patient-derived primary HER2+ Leptomeningeal carcinomatosis (Lepto) cell lines were established. RNA-seq in various breast cancer cell lines were conducted to characterize the established cell lines. Gene expression analysis clearly indicated thatt Lepto cell lines are transcriptionally different from HER2 positive and negative metastatic breast cancer cell lines such as BT474 and MDA-MB-231 cells.

2021-07-05 | GSE179280 | GEO

Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [CGH]

Project description:Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2 signaling pathway, and the molecular mechanisms related to treatment response were sought. To search for response predictors, genomic and transcriptomic profiling, PIK3CA mutations and PTEN status were associated to the drug responses and several genes involved in the response of the compounds were identified. Array-CGH experiments of HER2+ breast cancer cell lines grown under standard conditions. DNA from four HER2 positive breast cancer cell lines was isolated and hybridized on Agilent arrays.

2015-01-30 | E-GEOD-58886 | biostudies-arrayexpress

Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [Expression profiling]

Project description:Thirteen HER2 positive breast cancer cell lines were screened with 22 commercially available compounds, mainly targeting proteins in the ErbB2 signaling pathway, and the molecular mechanisms related to treatment response were sought. To search for response predictors, genomic and transcriptomic profiling, PIK3CA mutations and PTEN status were associated to the drug responses and several genes involved in the response of the compounds were identified. RNA from thirteen HER2 positive breast cancer cell lines was isolated and hybridized on Affymetrix arrays.

2015-01-30 | E-GEOD-58700 | biostudies-arrayexpress

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells

Project description:Array-CGH experiments of HER2+ breast cancer cell lines grown under standard conditions. All hybridizations performed using pooled normal female DNA as reference. 11 cell lines profiled in total, 10 HER2+, 1 HER2-. Each was hybridized once on an Agilent 244k aCGH microarray.

2013-06-01 | E-GEOD-34236 | biostudies-arrayexpress

Drug screening and genomic analyses of HER2 positive breast cancer cell lines reveal predictors for treatment response [CGH]

2015-01-30 | GSE58886 | GEO

HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer

Project description:Co-expression of the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) contributes to breast cancer heterogeneity and therapeutic resistance. Tumors expressing both ER and HER2 comprise up to 10% of diagnosed breast cancer cases, yet advances in the field have been hindered by the lack of suitable genetically engineered mouse models (GEMMs) to study the interactions between HER2 and ER in an immune-competent setting. Here, we demonstrate that expression of the oncogenic HER2 splice variant lacking exon 16 (HER2∆16) within the mammary epithelium promotes the development of aggressive luminal tumors, resembling HER2+/ER+ human breast cancer. Expression of HER2∆16 facilitates luminal cell differentiation and drives an ER-mediated transcriptional program that is sensitive to endocrine-based therapies in both murine and human models. Using a knock-in GEMM where HER2∆16 is under the transcriptional control of the endogenous murine ErbB2 promoter we show that this model recapitulates many features of HER2+/ER+ human breast cancer including genomic amplification of the endogenous ErbB2 allele, ER-expression and sensitivity to anti-estrogens, providing a vital preclinical platform to model ER+/HER2+ disease. HER2∆16 is expressed across HER2+ human breast cancer cell lines with higher levels correlating with increased expression of both ER and downstream transcriptional targets. Interestingly, expression of HER2∆16 is increased upon resistance to HER2-targeted therapy, leading to an ER-driven transcriptional program which can be effectively targeted using ER-antagonists. Overall, these findings offer valuable mechanistic insights into the therapeutic efficacy of combining anti-HER2 and endocrine therapy in tumors expressing high levels of the HER2∆16 isoform either in neoadjuvant or adjuvant settings to better treat HER2+ disease.

2026-05-16 | GSE301629 | GEO

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells

Project description:Array-CGH experiments of HER2+ breast cancer cell lines grown under standard conditions.

2013-06-01 | GSE34236 | GEO

HER2 RIME experiment from breast cancer specimen

Project description:RIME targeting ERBB2 (HER2) proteins was performed to analyse ERBB2 interactome to screen novel breast cancer diagnostic markers.

2025-09-09 | PXD061456 | JPOST Repository

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data